Notícias Kymera Therapeutics Inc - KYMR | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics Inc (KYMR) Notícias

Kymera Therapeutics Inc (KYMR)

32,54

-0,67

(-2,02%)

Fechado 22 Março 5:00PM

Atrasado por 15 minutos

32,54

-0,03

(-0,09%)

Após o horário de negociação: 8:52PM

Atrasado por 15 minutos

Discussões em tempo real e ideias de negociação: Negocie com confiança com nossa poderosa plataforma.

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Form 4 - Statement of changes in beneficial ownership of securities

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

2
3
4
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Kymera Therapeutics

iShares MSCI Brazil Smal...

Flushing Financial

Opendoor Technologies

Bath & Body Works

Nektar Therapeutics

GraniteShares 2X Long AM...

Horizon Bancorp

Columbia Sportswear

SPDR Portfolio Emerging ...

Hologic Inc Dl 01

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições